Genovis AB (publ.) (GENO.ST)
SEK 18.88
(-0.84%)
SEK 18.88
(-0.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 88.19 Million SEK | 19.75% |
| 2022 | 73.65 Million SEK | 22.38% |
| 2021 | 60.18 Million SEK | 12.87% |
| 2020 | 53.31 Million SEK | 25.07% |
| 2019 | 42.62 Million SEK | 30.11% |
| 2018 | 32.76 Million SEK | 10.49% |
| 2017 | 29.65 Million SEK | -22.07% |
| 2016 | 38.05 Million SEK | 6.65% |
| 2015 | 35.67 Million SEK | 38.46% |
| 2014 | 25.76 Million SEK | 11.89% |
| 2013 | 23.02 Million SEK | 15.1% |
| 2012 | 20 Million SEK | 121.4% |
| 2011 | 9.03 Million SEK | -24.91% |
| 2010 | 12.03 Million SEK | -3.31% |
| 2009 | 12.44 Million SEK | -49.29% |
| 2008 | 24.54 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 21.95 Million SEK | 7.09% |
| 2024 Q1 | 20.5 Million SEK | -14.12% |
| 2023 Q1 | 23.69 Million SEK | 58.83% |
| 2023 Q2 | 22.16 Million SEK | -6.46% |
| 2023 Q3 | 21.53 Million SEK | -2.85% |
| 2023 FY | 88.19 Million SEK | 19.75% |
| 2023 Q4 | 23.87 Million SEK | 10.85% |
| 2022 Q2 | 21.93 Million SEK | 13.57% |
| 2022 FY | 73.65 Million SEK | 22.38% |
| 2022 Q3 | 17.48 Million SEK | -20.3% |
| 2022 Q4 | 14.92 Million SEK | -14.65% |
| 2022 Q1 | 19.31 Million SEK | 18.83% |
| 2021 Q3 | 13.44 Million SEK | -16.03% |
| 2021 Q4 | 16.25 Million SEK | 20.86% |
| 2021 FY | 60.18 Million SEK | 12.87% |
| 2021 Q1 | 14.46 Million SEK | 18.16% |
| 2021 Q2 | 16.01 Million SEK | 10.71% |
| 2020 Q3 | 13.77 Million SEK | -4.61% |
| 2020 Q4 | 12.24 Million SEK | -11.1% |
| 2020 Q1 | 11.51 Million SEK | 26.59% |
| 2020 FY | 53.31 Million SEK | 25.07% |
| 2020 Q2 | 14.43 Million SEK | 25.41% |
| 2019 FY | 42.62 Million SEK | 30.11% |
| 2019 Q4 | 9.09 Million SEK | -34.08% |
| 2019 Q1 | 9.19 Million SEK | 30.8% |
| 2019 Q2 | 10.54 Million SEK | 14.59% |
| 2019 Q3 | 13.79 Million SEK | 30.88% |
| 2018 Q2 | 9.62 Million SEK | 24.4% |
| 2018 FY | 32.76 Million SEK | 10.49% |
| 2018 Q4 | 7.03 Million SEK | -17.65% |
| 2018 Q3 | 8.53 Million SEK | -11.24% |
| 2018 Q1 | 7.73 Million SEK | -4.12% |
| 2017 FY | 29.65 Million SEK | -22.07% |
| 2017 Q4 | 8.06 Million SEK | 23.39% |
| 2017 Q2 | 7.86 Million SEK | 12.5% |
| 2017 Q1 | 6.99 Million SEK | -10.64% |
| 2017 Q3 | 6.53 Million SEK | -16.9% |
| 2016 FY | 38.05 Million SEK | 6.65% |
| 2016 Q4 | 7.82 Million SEK | 29.9% |
| 2016 Q2 | 11.98 Million SEK | -1.85% |
| 2016 Q1 | 12.21 Million SEK | 118.28% |
| 2016 Q3 | 6.02 Million SEK | -49.76% |
| 2015 Q3 | 12.97 Million SEK | 34.88% |
| 2015 Q4 | 5.59 Million SEK | -56.87% |
| 2015 FY | 35.67 Million SEK | 38.46% |
| 2015 Q1 | 7.48 Million SEK | 14.32% |
| 2015 Q2 | 9.61 Million SEK | 28.46% |
| 2014 Q3 | 6.58 Million SEK | -7.76% |
| 2014 FY | 25.76 Million SEK | 11.89% |
| 2014 Q1 | 5.49 Million SEK | -6.07% |
| 2014 Q2 | 7.13 Million SEK | 29.94% |
| 2014 Q4 | 6.54 Million SEK | -0.53% |
| 2013 Q1 | 5.51 Million SEK | 1.04% |
| 2013 FY | 23.02 Million SEK | 15.1% |
| 2013 Q4 | 5.84 Million SEK | 6.5% |
| 2013 Q3 | 5.49 Million SEK | -10.96% |
| 2013 Q2 | 6.16 Million SEK | 11.76% |
| 2012 FY | 20 Million SEK | 121.4% |
| 2012 Q2 | 2.74 Million SEK | 10.05% |
| 2012 Q3 | 4.5 Million SEK | 63.77% |
| 2012 Q4 | 5.46 Million SEK | 21.33% |
| 2012 Q1 | 2.49 Million SEK | -1.5% |
| 2011 Q1 | 3.63 Million SEK | -54.84% |
| 2011 Q2 | 2.47 Million SEK | -32.08% |
| 2011 Q3 | 1.69 Million SEK | -31.61% |
| 2011 Q4 | 2.53 Million SEK | 50.06% |
| 2011 FY | 9.03 Million SEK | -24.91% |
| 2010 Q2 | 2.9 Million SEK | 21.4% |
| 2010 FY | 12.03 Million SEK | -3.31% |
| 2010 Q1 | 2.39 Million SEK | -67.49% |
| 2010 Q4 | 8.05 Million SEK | 599.29% |
| 2010 Q3 | 1.15 Million SEK | -60.33% |
| 2009 Q3 | 1.77 Million SEK | -37.35% |
| 2009 Q1 | 1.57 Million SEK | 0.0% |
| 2009 FY | 12.44 Million SEK | -49.29% |
| 2009 Q4 | 7.35 Million SEK | 314.47% |
| 2009 Q2 | 2.83 Million SEK | 80.45% |
| 2008 FY | 24.54 Million SEK | 0.0% |
| 2008 Q1 | 1.85 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | -96.829% |
| Amniotics AB (publ) | 29.07 Million SEK | -203.374% |
| BioArctic AB (publ) | 89.62 Million SEK | 1.596% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 94.175% |
| Camurus AB (publ) | 1.05 Billion SEK | 91.677% |
| Cantargia AB (publ) | 290.01 Million SEK | 69.589% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -302.818% |
| CombiGene AB (publ) | 44.14 Million SEK | -99.793% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 38.318% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 23.356% |
| Mendus AB (publ) | 129.13 Million SEK | 31.703% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1113.498% |
| Intervacc AB (publ) | 79.78 Million SEK | -10.543% |
| Kancera AB (publ) | 63.07 Million SEK | -39.824% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1498.061% |
| LIDDS AB (publ) | 27.75 Million SEK | -217.804% |
| Lipum AB (publ) | 37.3 Million SEK | -136.409% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1115.84% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 35.107% |
| NextCell Pharma AB | -576.01 Thousand SEK | 15411.474% |
| OncoZenge AB (publ) | 15.9 Million SEK | -454.524% |
| Saniona AB (publ) | 1.07 Million SEK | -8089.136% |
| Simris Alg AB (publ) | 38.64 Million SEK | -128.241% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 72.568% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 75.338% |
| Xintela AB (publ) | 57.31 Million SEK | -53.878% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 51.469% |
| Ziccum AB (publ) | 27.87 Million SEK | -216.368% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -501.904% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -211.36% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -437.754% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 71.28% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -106.88% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -398.767% |
| Corline Biomedical AB | 30.16 Million SEK | -192.353% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -51.983% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -6.046% |
| Aptahem AB (publ) | 10.01 Million SEK | -780.83% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 34.52% |
| Fluicell AB (publ) | 28.61 Million SEK | -208.198% |
| Biovica International AB (publ) | 133.72 Million SEK | 34.045% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -345.664% |
| AcouSort AB (publ) | 25.87 Million SEK | -240.845% |
| Abliva AB (publ) | 27.86 Million SEK | -216.504% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 54.42% |
| 2cureX AB (publ) | 36.51 Million SEK | -141.517% |
| I-Tech AB | 40.14 Million SEK | -119.68% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 89.738% |
| Cyxone AB (publ) | 28.21 Million SEK | -212.6% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 19.358% |
| Biosergen AB | 26.8 Million SEK | -228.983% |
| Nanologica AB (publ) | 69.88 Million SEK | -26.199% |
| SynAct Pharma AB | 224.49 Million SEK | 60.713% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -99.649% |
| BioInvent International AB (publ) | 441.4 Million SEK | 80.019% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -268.189% |
| Alzinova AB (publ) | 36.39 Million SEK | -142.326% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 69.561% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1022.632% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 20.482% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -499.98% |